<bill session="109" type="h" number="5922" updated="2023-01-12T17:52:34Z">
  <state datetime="2006-07-27">REFERRED</state>
  <status>
    <introduced datetime="2006-07-27"/>
  </status>
  <introduced datetime="2006-07-27"/>
  <titles>
    <title type="display">SAFE Drug Act</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs, to establish whistleblower protections for certain individuals, and for other purposes.</title>
    <title type="short" as="introduced">SAFE Drug Act</title>
    <title type="short" as="introduced">Swift Approval, Full Evaluation Drug Act</title>
  </titles>
  <sponsor bioguide_id="M000133"/>
  <cosponsors/>
  <actions>
    <action datetime="2006-07-27">
      <text>Introduced in House</text>
    </action>
    <action datetime="2006-07-27">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR E1569-1570"/>
    </action>
    <action datetime="2006-07-27" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2006-08-01">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Civil Rights and Liberties, Minority Issues"/>
    <term name="Civil actions and liability"/>
    <term name="Commerce"/>
    <term name="Communication in science"/>
    <term name="Congressional reporting requirements"/>
    <term name="Damages"/>
    <term name="Deceptive advertising"/>
    <term name="Department of Health and Human Services"/>
    <term name="Department of Labor"/>
    <term name="Disciplining of employees"/>
    <term name="Discrimination in employment"/>
    <term name="Dismissal of employees"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Federal employees"/>
    <term name="Federal officials"/>
    <term name="Fines (Penalties)"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government Operations and Politics"/>
    <term name="Informed consent (Medical law)"/>
    <term name="Labeling"/>
    <term name="Labor and Employment"/>
    <term name="Law"/>
    <term name="Legal fees"/>
    <term name="Marketing"/>
    <term name="Pharmaceutical research"/>
    <term name="Punitive damages"/>
    <term name="Science, Technology, Communications"/>
    <term name="Scientists in government"/>
    <term name="Wage restitution"/>
    <term name="Whistle blowing"/>
  </subjects>
  <amendments/>
  <summary date="2006-09-12T21:43:05Z" status="Introduced in House">Swift Approval, Full Evaluation Drug Act or the SAFE Drug Act - Amends the Federal Food, Drug, and Cosmetic Act to: (1) authorize the Secretary of Health and Human Services, upon receipt of evidence regarding the safety or lack of effectiveness of an approved drug, to order studies of such drug (postmarket studies) and place restrictions on the distribution or use of such drug during such studies; (2) require postmarket studies as a condition of approval of a new drug; (3) impose civil penalties for distributing misbranded or adulterated drugs or for failing to compete a required postmarket study; (4) label a drug misbranded if a drug manufacturer fails to make required postmarket labeling changes; (5) grant officers and employees of the Food and Drug Administration the right to publish or present data unless such data is subject to federal export control or national security laws or is proprietary information; and (6) require the Secretary to submit biennial reports to Congress on approved drug applications supported by non-inferiority studies and on postmarket studies.

Extends protections to individuals (whistleblowers) who provide information of illegal activity to government officials.</summary>
</bill>
